Polymorphisms in Phase i and Phase II genes and breast cancer risk and relations to persistent organic pollutant exposure: A case-control study in Inuit women

Environmental Health: A Global Access Science Source

Volumn 13, Issue 1, 2014, Pages

  Ghisari, Mandana ^a   Eiberg, Hans ^b   Long, Manhai ^a   Bonefeld Jørgensen, Eva C ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Breast cancer; COMT; CYP19; CYP1A1; CYP1B1; Genetic polymorphism; Inuit

Indexed keywords

AROMATASE; BRCA1 PROTEIN; CATECHOL METHYLTRANSFERASE; COTININE; CYTOCHROME P450 17; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; ESTRADIOL; PERFLUORO COMPOUND; PERFLUOROOCTANESULFONIC ACID; PERFLUOROOCTANOIC ACID; POLYCHLORINATED BIPHENYL; ALKANESULFONIC ACID; BRCA1 PROTEIN, HUMAN; COMT PROTEIN, HUMAN; CYTOCHROME P450; ESTROGEN; FLUOROCARBON; XENOBIOTIC AGENT;

CANCER; ESTROGENIC COMPOUND; GENE; GENOTYPE; INDIGENOUS POPULATION; MUTATION; ORGANIC POLLUTANT; POLLUTION EXPOSURE; POLYMORPHISM; RISK FACTOR; SENSITIVITY ANALYSIS; SERUM; XENOBIOTICS;

ADULT; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; ESTROGEN SYNTHESIS; FATTY ACID BLOOD LEVEL; FEMALE; GENE FREQUENCY; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; INUIT; MENOPAUSE; PERSISTENT ORGANIC POLLUTANT; POLYMERASE CHAIN REACTION; POPULATION EXPOSURE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; XENOBIOTIC METABOLISM; ADOLESCENT; AGED; BLOOD; BREAST TUMOR; ENVIRONMENTAL MONITORING; GENETICS; GREENLAND; METABOLISM; MIDDLE AGED; POLLUTANT; RISK; VERY ELDERLY; YOUNG ADULT;

ARCTIC; GREENLAND;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALKANESULFONIC ACIDS; BRCA1 PROTEIN; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CATECHOL O-METHYLTRANSFERASE; CYTOCHROME P-450 ENZYME SYSTEM; ENVIRONMENTAL MONITORING; ENVIRONMENTAL POLLUTANTS; ESTROGENS; FEMALE; FLUOROCARBONS; GREENLAND; HUMANS; INUITS; MIDDLE AGED; POLYCHLORINATED BIPHENYLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; XENOBIOTICS; YOUNG ADULT;

EID: 84926455555     PISSN: None     EISSN: 1476069X     Source Type: Journal    
DOI: 10.1186/1476-069X-13-19     Document Type: Article

References (65)

1. Fredslund SO, Bonefeld-Jorgensen EC: Breast cancer in the Arctic-changes over the past decades. Int J Circumpolar Health 2012, 71:19155.
2. Bonefeld-Jorgensen EC: Biomonitoring in Greenland: human biomarkers of exposure and effects - a short review. Rural Remote Health 2010, 10:1362.
3. Nielsen NH, Hansen JP: Breast cancer in Greenland-selected epidemiological, clinical, and histological features. J Cancer Res Clin Oncol 1980, 98:287-299. 10.1007/BF00410791
4. Friborg JT, Melbye M: Cancer patterns in Inuit populations. Lancet Oncol 2008, 9:892-900. 10.1016/S1470-2045(08)70231-6
5. Bozina N, Bradamante V, Lovric M: Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh Hig Rada Toksikol 2009, 60:217-242.
6. Nebert DW, Dalton TP: The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 2006, 6:947-960. 10.1038/nrc2015
7. Newbold RR, Liehr JG: Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. Cancer Res 2000, 60:235-237.
8. Liehr JG, Ricci MJ: 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc Natl Acad Sci 1996, 93:3294-3296. 10.1073/pnas.93.8.3294
9. Crofts F, Taioli E, Trachman J, Cosma GN, Currie D, Toniolo P, Garte SJ: Functional significance of different human CYP1A1 genotypes. Carcinogenesis 1994, 15:2961-2963. 10.1093/carcin/15.12.2961
10. Safe SH: Modulation of gene expression and endocrine response pathways by 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds. Pharmacol Ther 1995, 67:247-281. 10.1016/0163-7258(95)00017-B
11. Safe SH: Polychlorinated biphenyls (PCBs): environmental impact, biochemical and toxic responses, and implications for risk assessment. Crit Rev Toxicol 1994, 24:87-149. 10.3109/10408449409049308
12. Cascorbi I, Brockmoller J, Roots I: A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 1996, 56:4965-4969.
13. Cosma G, Crofts F, Taioli E, Toniolo P, Garte S: Relationship between genotype and function of the human CYP1A1 gene. J Toxicol Environ Health 1993, 40:309-316. 10.1080/15287399309531796
14. Shimada T, Watanabe J, Kawajiri K, Sutter TR, Guengerich FP, Gillam EM, Inoue K: Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 1999, 20:1607-1613. 10.1093/carcin/20.8.1607
15. Li DN, Seidel A, Pritchard MP, Wolf CR, Friedberg T: Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. Pharmacogenetics 2000, 10:343-353. 10.1097/00008571-200006000-00008
16. Paracchini V, Raimondi S, Gram IT, Kang D, Kocabas NA, Kristensen VN, Li D, Parl FF, Rylander-Rudqvist T, Soucek P, Zheng W, Wedren S, Taioli E: Meta- and pooled analyses of the cytochrome P-450 1B1 Val432Leu polymorphism and breast cancer: a HuGE-GSEC review. Am J Epidemiol 2007, 165:115-125.
17. Sergentanis TN, Economopoulos KP: Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2010, 122:459-469. 10.1007/s10549-009-0694-5
18. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I, Taskinen J: Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995, 34:4202-4210. 10.1021/bi00013a008
19. Dawling S, Roodi N, Mernaugh RL, Wang X, Parl FF: Catechol-O-methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res 2001, 61:6716-6722.
20. Mao C, Wang XW, Qiu LX, Liao RY, Ding H, Chen Q: Lack of association between catechol-O-methyltransferase Val108/158Met polymorphism and breast cancer risk: a meta-analysis of 25,627 cases and 34,222 controls. Breast Cancer Res Treat 2010, 121:719-725. 10.1007/s10549-009-0650-4
21. Ding H, Fu Y, Chen W, Wang Z: COMT Val158Met polymorphism and breast cancer risk: evidence from 26 case-control studies. Breast Cancer Res Treat 2010, 123:265-270. 10.1007/s10549-010-0759-5
22. Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S, Williamson R: Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994, 3:1873-1876. 10.1093/hmg/3.10.1873
23. Kristensen VN, Borresen-Dale AL: Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism. Mutat Res 2000, 462:323-333. 10.1016/S1383-5742(00)00018-1
24. Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE: Cytochrome P450c17α gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 1998, 58:585-587.
25. Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Speizer FE, Kelsey KT, Hunter DJ: The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 1999, 59:1015-1020.
26. Dumas I, Diorio C: Estrogen pathway polymorphisms and mammographic density. Anticancer Res 2011, 31:4369-4386.
27. Dunning AM, Dowsett M, Healey CS, Tee L, Luben RN, Folkerd E, Novik KL, Kelemen L, Ogata S, Pharoah PDP, Easton DF, Day NE, Ponder BAJ: Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 2004, 96:936-945. 10.1093/jnci/djh167
28. Ma XY, Qi XW, Chen CH, Lin H, Xiong HY, Li YF, Jiang J: Association between CYP19 polymorphisms and breast cancer risk: results from 10,592 cases and 11,720 controls. Breast Cancer Res Treat 2010, 122:495-501. 10.1007/s10549-009-0693-6
29. Olson SH, Bandera EV, Orlow I: Variants in estrogen biosynthesis genes, sex steroid hormone levels, and endometrial cancer: a HuGE review. Am J Epidemiol 2007, 165:235-245.
30. Laden F, Ishibe N, Hankinson SE, Wolff MS, Gertig DM, Hunter DJ, Kelsey KT: Polychlorinated biphenyls, cytochrome P450 1A1, and breast cancer risk in the Nurses' Health Study. Cancer Epidemiol Biomarkers Prev 2002, 11:1560-1565.
31. Moysich KB, Shields PG, Freudenheim JL, Schisterman EF, Vena JE, Kostyniak P, Greizerstein H, Marshall JR, Graham S, Ambrosone CB: Polychlorinated biphenyls, cytochrome P4501A1 polymorphism, and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999, 8:41-44.
32. Zhang Y, Wise JP, Holford TR, Xie H, Boyle P, Zahm SH, Rusiecki J, Zou K, Zhang B, Zhu Y, Owens PH, Zheng T: Serum polychlorinated biphenyls, cytochrome P-450 1A1 polymorphisms, and risk of breast cancer in Connecticut women. Am J Epidemiol 2004, 160:1177-1183. 10.1093/aje/kwh346
33. Bonefeld-Jorgensen EC, Long M, Bossi R, Ayotte P, Asmund G, Kruger T, Ghisari M, Mulvad G, Kern P, Nzulumiki P, Dewailly E: Perfluorinated compounds are related to breast cancer risk in Greenlandic Inuit: a case control study. Environ Health 2011, 10:88. 10.1186/1476-069X-10-88
34. Ghisari M, Long M, Bonefeld-Jorgensen EC: Genetic polymorphisms in CYP1A1, CYP1B1 and COMT genes in Greenlandic Inuit and Europeans. Int J Circumpolar Health 2013, 72:21113.
35. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano R, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, et al.: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66-71. 10.1126/science.7545954
36. Harboe TL, Eiberg H, Kern P, Ejlertsen B, Nedergaard L, Timmermans-Wielenga V, Nielsen IM, Bisgaard ML: A high frequent BRCA1 founder mutation identified in the Greenlandic population. Fam Cancer 2009, 8:413-419. 10.1007/s10689-009-9257-5
37. Yager JD, Davidson NE: Estrogen carcinogenesis in breast cancer. N Engl J Med 2006, 354:270-282. 10.1056/NEJMra050776
38. Rudkowska I, Dewailly E, Hegele RA, Boiteau V, Dube-Linteau A, Abdous B, Giguere Y, Chateau-Degat ML, Vohl MC: Gene-diet interactions on plasma lipid levels in the Inuit population. Br J Nutr 2013, 109:953-961. 10.1017/S0007114512002231
39. Zhang L, Gu L, Qian B, Hao X, Zhang W, Wei Q, Chen K: Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women. Breast Cancer Res Treat 2009, 114:327-338. 10.1007/s10549-008-9998-0
40. Asghar T, Yoshida S, Nakago S, Morizane M, Ohara N, Motoyama S, Kennedy S, Barlow D, Maruo T: Lack of association between endometriosis and the CYP17 MspA1 polymorphism in UK and Japanese populations. Gynecol Endocrinol 2005, 20:59-63. 10.1080/09513590400020856
41. Haiman CA, Stram DO, Pike MC, Kolonel LN, Burtt NP, Altshuler D, Hirschhorn J, Henderson BE: A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort. Hum Mol Genet 2003, 12:2679-2692. 10.1093/hmg/ddg294
42. Chen S, Xue K, Xu L, Ma G, Wu J: Polymorphisms of the CYP1A1 and GSTM1 genes in relation to individual susceptibility to lung carcinoma in Chinese population. Mutat Res 2001, 458:41-47.
43. Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, Laughlin R, Nemoto T, Michalek AM, Harrington A, Ford TD, Shields PG: Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res 1995, 55:3483-3485.
44. Ishibe N, Hankinson SE, Colditz GA, Spiegelman D, Willett WC, Speizer FE, Kelsey KT, Hunter DJ: Cigarette smoking, cytochrome P450 1A1 polymorphisms, and breast cancer risk in the Nurses' Health Study. Cancer Res 1998, 58:667-671.
45. Li Y, Millikan RC, Bell DA, Cui L, Tse CK, Newman B, Conway K: Polychlorinated biphenyls, cytochrome P450 1A1 (CYP1A1) polymorphisms, and breast cancer risk among African American women and white women in North Carolina: a population-based case-control study. Breast Cancer Res 2005, 7:R12-R18.
46. Mortensen AS, Letcher RJ, Cangialosi MV, Chu S, Arukwe A: Tissue bioaccumulation patterns, xenobiotic biotransformation and steroid hormone levels in Atlantic salmon (Salmo salar) fed a diet containing perfluoroactane sulfonic or perfluorooctane carboxylic acids. Chemosphere 2011, 83:1035-1044. 10.1016/j.chemosphere.2011.01.067
47. Wy H, Jones PD, DeCoen W, King L, Fraker P, Newsted J, Giesy JP: Alterations in cell membrane properties caused by perfluorinated compounds. Comp Biochem Physiol C Toxicol Pharmacol 2003, 135:77-88. 10.1016/S1532-0456(03)00043-7
48. Long M, Ghisari M, Bonefeld-Jorgensen EC: Effects of perfluoroalkyl acids on the function of the thyroid hormone and the aryl hydrocarbon receptor. Environ Sci Pollut Res Int 2013, 20:8045-8056. 10.1007/s11356-013-1628-7
49. Bailey LR, Roodi N, Dupont WD, Parl FF: Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res 1998, 58:5038-5041.
50. Wang Q, Li H, Tao P, Wang YP, Yuan P, Yang CX, Li JY, Yang F, Lee H, Huang Y: Soy isoflavones, CYP1A1, CYP1B1, and COMT polymorphisms, and breast cancer: a case-control study in southwestern China. DNA Cell Biol 2011, 30:585-595. 10.1089/dna.2010.1195
51. Shimada T, Watanabe J, Inoue K, Guengerich FP, Gillam EM: Specificity of 17beta-oestradiol and benzo[a]pyrene oxidation by polymorphic human cytochrome P4501B1 variants substituted at residues 48, 119 and 432. Xenobiotica 2001, 31:163-176. 10.1080/00498250110043490
52. Wen W, Ren Z, Shu XO, Cai Q, Ye C, Gao YT, Zheng W: Expression of cytochrome P450 1B1 and catechol-O-methyltransferase in breast tissue and their associations with breast cancer risk. Cancer Epidemiol Biomarkers Prev 2007, 16:917-920. 10.1158/1055-9965.EPI-06-1032
53. Nock NL, Cicek MS, Li L, Liu X, Rybicki BA, Moreira A, Plummer SJ, Casey G, Witte JS: Polymorphisms in estrogen bioactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk. Carcinogenesis 2006, 27:1842-1848. 10.1093/carcin/bgl022
54. Goodman MT, McDuffie K, Kolonel LN, Terada K, Donlon TA, Wilkens LR, Guo C, Le Marchand L: Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol Biomarkers Prev 2001, 10:209-216.
55. Cerne JZ, Pohar-Perme M, Novakovic S, Frkovic-Grazio S, Stegel V, Gersak K: Combined effect of CYP1B1, COMT, GSTP1, and MnSOD genotypes and risk of postmenopausal breast cancer. J Gynecol Oncol 2011, 22:110-119. 10.3802/jgo.2011.22.2.110
56. Nedelcheva Kristensen V, Haraldsen EK, Anderson KB, Lonning PE, Erikstein B, Karesen R, Gabrielsen OS, Borresen-Dale AL: CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1. Cancer Res 1999, 59:2825-2828.
57. García-Closas M, Herbstman J, Schiffman M, Glass A, Dorgan JF: Relationship between serum hormone concentrations, reproductive history, alcohol consumption and genetic polymorphisms in pre-menopausal women. Int J Cancer 2002, 102:172-178. 10.1002/ijc.10651
58. Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Vainio H, Uusitupa M, Hirvonen A: Steroid metabolism gene CYP17 polymorphism and the development of breast cancer. Cancer Epidemiol Biomarkers Prev 2000, 9:1343-1348.
59. Haiman CA, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I: A polymorphism in CYP17 and endometrial cancer risk. Cancer Res 2001, 61:3955-3960.
60. Chen Y, Pei J: Factors influencing the association between CYP17 T34C polymorphism and the risk of breast cancer: meta-regression and subgroup analysis. Breast Cancer Res Treat 2010, 122:471-481. 10.1007/s10549-009-0690-9
61. Yao L, Fang F, Wu Q, Yang Z, Zhong Y, Yu L: No association between CYP17 T-34C polymorphism and breast cancer risk: a meta-analysis involving 58,814 subjects. Breast Cancer Res Treat 2010, 122:221-227. 10.1007/s10549-009-0679-4
62. Lau C: Perfluorinated compounds. EXS 2012, 101:47-86.
63. Kjeldsen LS, Bonefeld-Jorgensen EC: Perfluorinated compounds affect the function of sex hormone receptors. Environ Sci Pollut Res Int 2013, 20:8031-8044. 10.1007/s11356-013-1753-3
64. Henry ND, Fair PA: Comparison of in vitro cytotoxicity, estrogenicity and anti-estrogenicity of triclosan, perfluorooctane sulfonate and perfluorooctanoic acid. J Appl Toxicol 2013, 33:265-272. 10.1002/jat.1736
65. Benninghoff AD, Bisson WH, Koch DC, Ehresman DJ, Kolluri SK, Williams DE: Estrogen-like activity of perfluoroalkyl acids in vivo and interaction with human and rainbow trout estrogen receptors in vitro. Toxicol Sci 2011, 120:42-58. 10.1093/toxsci/kfq379